scholarly journals Long-term antidepressant treatment in general practice: changes in body mass index

2016 ◽  
Vol 40 (6) ◽  
pp. 310-314 ◽  
Author(s):  
Laura Chiwanda ◽  
Matthew Cordiner ◽  
Anne T. Thompson ◽  
Polash Shajahan
Keyword(s):  
Body Mass Index ◽  
General Practice ◽  
Body Mass ◽  
Antidepressant Treatment ◽  
Term Treatment ◽  
Metabolic Effects ◽  
Practice Population ◽  
Long Term Treatment ◽  
Patients With Diabetes

Aims and methodTo discern changes in body mass index (BMI) in patients on long-term antidepressant treatment in a general practice population and establish BMI changes in patients with and without a diagnosis of diabetes. We used a retrospective observational method and identified patients on four antidepressants of interest. We excluded those who did not have start and current BMI readings within the past 3 years and noted whether or not patients had a diagnosis of diabetes.ResultsLong-term treatment with citalopram, fluoxetine, mirtazapine and sertraline was associated with increased BMI in two-thirds of patients. There was reduction in BMI in patients with diabetes and an increase in BMI for patients who did not have diabetes.Clinical implicationsAwareness of environmental factors and their impact on individuals is important. Medication is not the only cause of abnormal metabolic effects. Overall monitoring of physical health is important in all groups of patients.

scholarly journals Body mass index and blood glucose in psychiatric and general practice populations

2016 ◽  
Vol 40 (3) ◽  
pp. 127-131 ◽  
Author(s):  
Sarah McAvoy ◽  
Matthew Cordiner ◽  
Jackie Kelly ◽  
Laura Chiwanda ◽  
Christine Jefferies ◽  
...  
Keyword(s):  
Body Mass Index ◽  
General Practice ◽  
Blood Glucose ◽  
Environmental Factors ◽  
Body Mass ◽  
Psychiatric Illness ◽  
Metabolic Parameters ◽  
Metabolic Effects ◽  
Clinical Implications ◽  
Practice Population

Aims and methodUsing a retrospective observational approach, we aimed to discern whether there was a difference in metabolic parameters between psychiatric and general practice populations in the same locality. Second, we aimed to establish differences in metabolic parameters of patients taking olanzapine, clozapine or aripiprazole.ResultsPatients with psychiatric illness had a body mass index (BMI) comparable to that of the general practice population (28.7 v. 29.7 kg/m2), but blood glucose was significantly lower in the general practice population (4.8 v. 6.1 mmol/L). Olanzapine was associated with the lowest BMI (26.1 kg/m2) and aripiprazole the highest (32.2 kg/m2), with no difference in blood glucose between antipsychotics.Clinical implicationsAwareness of environmental factors and how they affect individuals is important and medications are not the only cause of metabolic effects. There may be a channelling bias present, meaning practitioners are cognisant of potential metabolic effects prior to prescribing. Overall monitoring of physical health is important regardless of potential cause.

scholarly journals Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate

2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Jennifer Kern Sliwa ◽  
Dong-Jing Fu ◽  
Cynthia A Bossie ◽  
Ibrahim Turkoz ◽  
Larry Alphs
Keyword(s):  
Body Mass Index ◽  
Body Mass ◽  
Term Treatment ◽  
Metabolic Parameters ◽  
Paliperidone Palmitate ◽  
Long Term Treatment

Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment

Diabetes Care ◽  
1987 ◽  
Vol 10 (6) ◽  
pp. 71-78 ◽  
Author(s):  
L. Groop ◽  
P. H. Groop ◽  
S. Stenman ◽  
C. Saloranta ◽  
K. J. Totterman ◽  
...  
Keyword(s):  
Mechanisms Of Action ◽  
Term Treatment ◽  
Metabolic Effects ◽  
Long Term Treatment

Long-term Treatment with Bendroflumethiazide for Prevention of Stones. Metabolic Effects

Urolithiasis ◽  
1981 ◽  
pp. 245-248 ◽  
Author(s):  
S. Ljunghall ◽  
U. Backman ◽  
B. G. Danielson ◽  
B. Fellström ◽  
G. Johansson ◽  
...  
Keyword(s):  
Term Treatment ◽  
Metabolic Effects ◽  
Long Term Treatment

Antihypertensive and metabolic effects of long-term treatment with amosulalol in non-insulin dependent diabetics

1992 ◽  
Vol 12 (9) ◽  
pp. 564-571 ◽  
Author(s):  
Y. Inoue ◽  
K. Yaga ◽  
M. Nishimura ◽  
K. Okafuji ◽  
Y. Fujii ◽  
...  
Keyword(s):  
Term Treatment ◽  
Metabolic Effects ◽  
Long Term Treatment ◽  
Insulin Dependent

Long-term lithium treatment in the prevention of suicidal behavior in bipolar disorder patients

2009 ◽  
Vol 18 (3) ◽  
pp. 179-183 ◽  
Author(s):  
Leonardo Tondo ◽  
Ross J. Baldessarini
Keyword(s):  
Bipolar Disorder ◽  
Suicidal Behavior ◽  
Antidepressant Treatment ◽  
Lithium Treatment ◽  
Term Treatment ◽  
Mood Stabilizers ◽  
Major Depressive ◽  
Long Term Treatment ◽  
Meta Analyses

AbstractWe reviewed available research findings, including meta-analyses on effects of lithium-treatment associated with rates of suicidal behavior in bipolar disorder or unipolar major depressive disorder patients, and for comparisons of lithium to mood-stabilizing anticonvulsants. Data from meta-analyses consistently indicate marked reductions of suicidal behavior and mortality during long-term treatment with lithium salts in bipolar disorder patients, and possibly also in unipolar, recurrent major depressive, perhaps even more effectively than with anticonvulsants proposed as mood-stabilizers. Suicidal risk is frequently associated with dysphoric-agitated symptoms, anger, aggression, and impulsivity-all of which may respond better to treatment with lithium or other mood-stabilizing medicines than to antidepressants. In these conditions, antidepressant treatment may not provide a beneficial effect on risk of suicidal thoughts and perhaps attempts, particularly in juveniles, whereas, lithium, perhaps even more than anticonvulsants, seems to be remarkably effective in the preventing suicidal behavior. The mechanism of action is not well defined and may be associated with either a prevention of mood recurrences or a more specific “antisuicidal” activity.Declaration of Interest: Dr. Tondo has received research support from Janssen and Eli Lilly Corporations and has served as a consultant to Glaxo-SmithKline and Merck Corporations. Dr. Baldessarini has recently been a consultant or investigator-initiated research collaborator with: AstraZeneca, Auritec, Biotrofix, Janssen, JDS-Noven, Lilly, Luitpold, NeuroHealing, Novartis, Pfizer, and SK-BioPharmaceutical Corporations. Neither author is a member of pharmaceutical speakers’ bureaus, nor do they or any family member hold equity positions in biomedical or pharmaceutical corporations.

Sign in / Sign up

Export Citation Format

Share Document